Biodel Company Description
Biodel delves into the development of viable treatments for endocrine disorders. The company uses its VIAdel biological technology to reformulate and administer existing peptide drugs. Its two main product candidates are in clinical trials for treating diabetes. Biodel's VIAject insulin formula is designed to be rapidly absorbed into the bloodstream following injection, while its VIAtab insulin tablets are administered orally. Two additional products aimed at treating osteoporosis, VIAmass and VIAcal, are in preclinical development. Members of Biodel's board of directors together own more than 50% of the company; prior to its 2007 IPO board members controlled over 80% of Biodel.
View the Comprehensive Company Description for Biodel
The Company Description provides a historical perspective of Biodel's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Biodel's evolution in the marketplace.
